Compare AUPH & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUPH | AZTA |
|---|---|---|
| Founded | 1993 | 1978 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2014 | 1996 |
| Metric | AUPH | AZTA |
|---|---|---|
| Price | $14.34 | $24.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $17.25 | ★ $42.60 |
| AVG Volume (30 Days) | ★ 857.6K | 756.9K |
| Earning Date | 05-25-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5075.00 | 60.52 |
| EPS | ★ 2.07 | N/A |
| Revenue | $283,055,000.00 | ★ $593,821,000.00 |
| Revenue This Year | $17.35 | $6.25 |
| Revenue Next Year | $15.66 | $5.42 |
| P/E Ratio | $7.11 | ★ N/A |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $6.83 | $23.77 |
| 52 Week High | $16.54 | $45.26 |
| Indicator | AUPH | AZTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 24.86 |
| Support Level | $13.52 | N/A |
| Resistance Level | $16.28 | $31.87 |
| Average True Range (ATR) | 0.54 | 1.10 |
| MACD | 0.05 | -0.19 |
| Stochastic Oscillator | 46.51 | 7.16 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.